THEMISMEDPharmaceuticals
Themis Medicare Ltd — Profit & Loss Statement
₹66.07
-9.59%
Themis Medicare Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.01 Cr | 79646.25 | — |
| Tax Rate For Calcs | 0.25 | 0.19 | 0.22 | 0.23 | — |
| Normalized EBITDA | 59.64 Cr | 75.07 Cr | 90.95 Cr | 111.24 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Reconciled Depreciation | 9.93 Cr | 12.25 Cr | 10.49 Cr | 9.48 Cr | — |
| Reconciled Cost Of Revenue | 131.99 Cr | 136.71 Cr | 121.00 Cr | 151.99 Cr | — |
| EBITDA | 59.64 Cr | 75.07 Cr | 91.00 Cr | 111.28 Cr | — |
| EBIT | 49.71 Cr | 62.82 Cr | 80.51 Cr | 101.80 Cr | — |
| Net Interest Income | -10.04 Cr | -9.38 Cr | -9.02 Cr | -8.17 Cr | — |
| Interest Expense | 10.04 Cr | 9.38 Cr | 7.99 Cr | 6.54 Cr | — |
| Normalized Income | 29.83 Cr | 43.52 Cr | 56.86 Cr | 72.85 Cr | — |
| Net Income From Continuing And Discontinued Operation | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Total Expenses | 366.39 Cr | 342.50 Cr | 287.50 Cr | 305.19 Cr | — |
| Diluted Average Shares | 9.21 Cr | 9.22 Cr | 9.22 Cr | 9.22 Cr | — |
| Basic Average Shares | 9.21 Cr | 9.20 Cr | 9.20 Cr | 9.20 Cr | — |
| Diluted EPS | 3.24 | 4.72 | 6.17 | 7.91 | — |
| Basic EPS | 3.24 | 4.73 | 6.18 | 7.92 | — |
| Diluted NI Availto Com Stockholders | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Net Income Common Stockholders | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Minority Interests | 2000.00 | 3000.00 | 2000.00 | 1000.00 | — |
| Net Income Including Noncontrolling Interests | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Net Income Continuous Operations | 29.83 Cr | 43.52 Cr | 56.90 Cr | 72.88 Cr | — |
| Tax Provision | 9.84 Cr | 9.92 Cr | 15.61 Cr | 22.38 Cr | — |
| Pretax Income | 39.67 Cr | 53.44 Cr | 72.51 Cr | 95.26 Cr | — |
| Other Non Operating Income Expenses | 4.67 Cr | 4.76 Cr | 3.47 Cr | 1.26 Cr | — |
| Net Non Operating Interest Income Expense | -10.04 Cr | -9.38 Cr | -9.02 Cr | -8.17 Cr | — |
| Interest Expense Non Operating | 10.04 Cr | 9.38 Cr | 7.99 Cr | 6.54 Cr | — |
| Operating Income | 39.12 Cr | 39.26 Cr | 56.96 Cr | 86.16 Cr | — |
| Operating Expense | 234.40 Cr | 205.79 Cr | 166.50 Cr | 153.20 Cr | — |
| Other Operating Expenses | 128.10 Cr | 111.13 Cr | 71.55 Cr | 66.18 Cr | — |
| Depreciation And Amortization In Income Statement | 9.93 Cr | 12.25 Cr | 10.49 Cr | 9.48 Cr | — |
| Depreciation Income Statement | 9.93 Cr | 12.25 Cr | 10.28 Cr | 9.26 Cr | — |
| Gross Profit | 273.52 Cr | 245.05 Cr | 223.46 Cr | 239.35 Cr | — |
| Cost Of Revenue | 131.99 Cr | 136.71 Cr | 121.00 Cr | 151.99 Cr | — |
| Total Revenue | 405.51 Cr | 381.76 Cr | 344.45 Cr | 391.35 Cr | — |
| Operating Revenue | 405.51 Cr | 381.76 Cr | 344.45 Cr | 391.35 Cr | — |
| Total Unusual Items | — | 0.00 | 0.05 Cr | 0.03 Cr | 0.02 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.00 | 0.05 Cr | 0.03 Cr | 0.02 Cr |
| Interest Income | — | 0.84 Cr | 0.55 Cr | 0.61 Cr | 0.41 Cr |
| Rent Expense Supplemental | — | 2.17 Cr | 1.81 Cr | 0.98 Cr | 0.83 Cr |
| Average Dilution Earnings | — | 0.00 | 0.00 | — | — |
| Special Income Charges | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Other Finance Cost | — | 1.75 Cr | 1.57 Cr | 2.24 Cr | 1.75 Cr |
| Interest Income Non Operating | — | 0.84 Cr | 0.55 Cr | 0.61 Cr | 0.41 Cr |
| Amortization | — | 0.22 Cr | 0.22 Cr | 0.22 Cr | 0.22 Cr |
| Selling General And Administration | — | 33.26 Cr | 26.37 Cr | 27.85 Cr | 16.16 Cr |
| Selling And Marketing Expense | — | 22.36 Cr | 17.03 Cr | 17.93 Cr | 9.47 Cr |
| General And Administrative Expense | — | 10.90 Cr | 9.34 Cr | 9.92 Cr | 6.69 Cr |
| Rent And Landing Fees | — | 2.17 Cr | 1.81 Cr | 0.98 Cr | 0.83 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Themis Medicare Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.